Oncology

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.

The annual cost of treating cancer is projected to rise to $173 billion by 2020, a 39% increase since 2010.

Nancy Egerton, PharmD, BCOP, discusses the pharmacist's role in oncology care.

Combination of Lenvima and Keytruda awarded second Breakthrough Therapy designation for the treatment of endometrial carcinoma.

Advancements in breast cancer treatment have improved survival rates, but financial hardships related to the cost of these lifesaving therapies can weigh heavily on patients.

Survey findings indicate that patients with breast cancer worry about financial hardships related to their treatment, yet many do not feel providers adequately address these concerns.

Study investigates complementary medicine use in patients with curable cancer types and its impact on survival and adherence to conventional therapy.

Top news of the day from across the health care landscape.

A recent systematic review and meta-analysis found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.

Genentech announced that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer.

This is the first approval that the FDA has granted as part of its new approaches to streamlining the development and review of oncology drugs.

Approximately 80% of manufacturers are already managing their products, many of which are oncology drugs, through a limited distribution model.

The discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.

Enzalutamide (Xtandi) is the first and only FDA-approved oral medication for both non-metastatic and metastatic castration-resistant prostate cancer.

With this new indication, enzalutamide is the first and only FDA-approved oral medication for both non-metastatic and metastatic CRPC.

A look at last week's top stories in the world of pharmacy.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) approved for patients with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Hepatocellular carcinoma is the most common type of liver cancer in adults.

Approvals and indications of this drug were based on 3 main clinical trials.

New research identified predictors of long-term survival and health-related quality of life in patients with newly diagnosed multiple myeloma.

In the phase 3 PALOMA-3 trial, Pfizer’s palbociclib (Ibrance) narrowly missed reaching its secondary endpoint of overall survival (OS), according to a press release.

The PALOMA-3 trial evaluated palbociclib (Ibrance) in combination with fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

Researchers have developed a laser-sonic scanner with the ability to detect tumors in as little as 15 seconds.

Using a DNA test to identify genetic variants in men that increase the likelihood of prostate cancer may help guide interventions for those at high risk and improve disease prevention.

Top news of the day from across the health care landscape.

Using real-time symptom reports, a well-trained classification algorithm can detect lymphedema more accurately than current clinical methods.

Atezolizumab (Tecentriq, Roche) plus chemotherapy nab-paclitaxel (Abraxane) met its co-primary endpoint of progression-free survival in patients with metastatic triple-negative breast cancer.

Atezolizumab (Tecentriq) plus chemotherapy nab-paclitaxel (Abraxane) significantly reduced the risk of disease worsening or death in patients with metastatic triple-negative breast cancer.